Publications by authors named "Annika Folin"
Unlabelled: On August 28, 2015, a marketing authorization valid through the European Union was issued for panobinostat, in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent (IMiD).Panobinostat is an orally available histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDAC proteins at nanomolar concentrations. HDAC proteins catalyze the removal of acetyl groups from the lysine residues of histones and some nonhistone proteins.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness of adjuvant chemotherapy and accelerated radiotherapy in adults with high-risk soft tissue sarcoma in the extremities or trunk wall.
- High-risk was defined by factors like large tumor size, vascular invasion, and necrosis, with patients receiving six cycles of doxorubicin and ifosfamide alongside targeted radiotherapy.
- Results showed a 5-year overall survival of 68%, with lower local recurrence rates in patients receiving 36 Gy of radiotherapy compared to those receiving a higher dose, highlighting vascular invasion as a key factor impacting survival outcomes.
The growth of many soft tissue sarcomas is dependent on aberrant growth factor signaling, which promotes their proliferation and motility. With this in mind, we evaluated the effect of sorafenib, a receptor tyrosine kinase inhibitor, on cell growth and apoptosis in sarcoma cell lines of various histological subtypes. We found that sorafenib effectively inhibited cell proliferation in rhabdomyosarcoma, synovial sarcoma and Ewing's sarcoma with IC(50) values <5 μM.
View Article and Find Full Text PDFPurpose: We reviewed follow-up of patients treated in 19 randomized trials of adjuvant epirubicin in early breast cancer to determine incidence, risk, and risk factors for subsequent acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Patients And Methods: The patients (N = 9,796) were observed from the start of adjuvant treatment (53,080 patient-years). Cases of AML or MDS (AML/MDS) were reported, with disease characteristics.